Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIMES: Qiqi Shengmai Formula for Moyamoya Vasculopathy
NCT07286110Phase 1Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Qiqi Shengmai Formula in Moyamoya disease (2 arms), sponsored by Fudan University. Primary endpoint: Computed Tomography Perfusion at 12 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
Qiqi Shengmai Formula
03
Conditions
Moyamoya disease
Beyond the preview
Go deeper on NCT07286110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286110.